NCT03824171View on ClinicalTrials.gov

Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

March 27, 2019

Study Completion Date

April 8, 2019

Conditions
Osteoporosis
Interventions
DRUG

Raloxifene 60mg/Cholecalciferol 800IU

Raloxifene 60mg/Cholecalciferol 800IU tablet

DRUG

AD-102

AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet

Trial Locations (1)

Unknown

Korea University Guro Hosptial, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT03824171 - Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers | Biotech Hunter | Biotech Hunter